Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du
about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondNew criteria for response assessment: role of minimal residual disease in multiple myelomaRecent advances in understanding multiple myelomaOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceFlow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaExtended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativHigh expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myelomaSubcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Multiple myeloma in the marrow: pathogenesis and treatments.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyTreatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Clinical treatment of newly diagnosed multiple myeloma.Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.Oral ixazomib maintenance therapy in multiple myeloma.Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.The role of tandem stem cell transplantation for multiple myeloma patients.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical TrialsManagement of high-risk Myeloma: an evidence-based review of treatment strategies.Multiple myeloma: disease response assessment.Multiple Myeloma Minimal Residual Disease.Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
P2860
Q26766718-707920CE-CBC7-4CFA-9853-9B7F2C36EF93Q27027512-0974BB5D-961F-4FAD-9B6E-28FACAD48162Q28070331-8253621F-7F84-45D9-9F83-9EC39BCB6F5AQ28077567-17E675C3-D6FA-4A05-83DD-F7826D39A6A2Q33602593-E390D6CA-19CB-456A-AD97-2DD3DE3A6443Q34551324-BADC1BA8-1AA0-433A-86F7-24FFFB707844Q34694749-EE2E9EA7-56A4-490F-8DDD-7C7AA5A5DE54Q35571048-F8924790-B99C-4D67-AD2D-211A85B76784Q35789280-E87BB9EE-5ABB-4491-BFD6-0DB97E49B008Q35800851-77AD0C9C-E076-4604-99C3-A47F866B0E4CQ36000415-819F23BD-4289-4B83-80CD-9244A1785EF0Q36725401-7211397B-0CE2-4437-B47A-A0A3F26E6261Q36963203-8A53B40D-5A12-4879-9130-1CF486F08E5FQ37037265-A716D422-C64A-482B-B5A7-4BECE9594CC2Q37373159-36FF8E98-BC87-4ECE-A936-97939AD10181Q38375463-61C937E3-E29F-4282-B74B-D9ED5A2B628EQ38385471-BB58ADE9-6F75-4F71-9D25-7EB7CEC968BFQ38413040-214EC6FA-5FFC-47DF-BD85-8FD59DA54EF3Q38429817-61683DE5-6439-47E0-BB64-AE563F2555FAQ38534837-A20FC4D0-622D-41F5-A7BE-64EBD0D327F5Q38545607-D2D10DDD-382F-495C-8A79-0A081A5AE6D6Q38578071-0D5EB5D0-A574-41AB-93F3-D2F1A3CA978FQ38632778-0FF37DFA-EA0F-4FE3-BDC9-466AB3732C36Q38640514-ADF631F7-61F4-45B2-BE49-DC47974003A8Q38650700-7A34FD8F-1AE4-4251-9D78-DAFB57816709Q38677358-D6FF97EC-B4FD-4DE7-BD32-68D51CE9CBC6Q38691698-C85598B9-ECCF-4F07-9097-172B9D2F9975Q38738098-FBAE80CF-FC37-42DF-9E51-3248DA484BF0Q38740213-47B07CA2-A0D2-48AD-99AB-7E44F5A38367Q38771752-895726D8-2AD5-46A0-879C-E16BEB09944EQ38789282-339079A4-2B3C-48A3-848C-6D4309FE19B3Q38874675-D375D15D-4908-43BE-81FE-3073373C86A5Q38895092-D4B1A2B5-F31C-4A05-98FE-3C40712B32ACQ38970590-A0AC3F2F-C6EE-4A7D-A682-0CA96F02BAF3Q38970962-1ACC102A-8FB4-4252-B774-A537CA467732Q38979403-78426313-7228-4565-8854-57C9F51719A3Q39013004-6085590F-4090-4A01-AA2C-9586BB0632E0Q39065368-73E04DEE-84D4-4851-BE36-7786E1754F16Q39103567-114FD964-BD0D-4171-89EF-C875C4DD3B66Q39386287-C313DBBF-4CD9-4DF5-971B-8344D45167E0
P2860
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Front-line transplantation pro ...... the Intergroupe Francophone du
@ast
Front-line transplantation pro ...... the Intergroupe Francophone du
@en
type
label
Front-line transplantation pro ...... the Intergroupe Francophone du
@ast
Front-line transplantation pro ...... the Intergroupe Francophone du
@en
prefLabel
Front-line transplantation pro ...... the Intergroupe Francophone du
@ast
Front-line transplantation pro ...... the Intergroupe Francophone du
@en
P2093
P50
P356
P1476
Front-line transplantation pro ...... the Intergroupe Francophone du
@en
P2093
Anne Huynh
Anne-Marie Stoppa
Benjamin Hebraud
Catherine Gentil
Christophe Fruchart
Denis Caillot
Gérald Marit
Lotfi Benboubker
Marie-Lorraine Chretien
Nelly Robillard
P304
P356
10.1200/JCO.2013.54.8164
P407
P50
P577
2014-07-14T00:00:00Z